RCUS
Live chart
What they do
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
For information only · Important disclosures
Grades vs sector
Momentum66th percentile in sectorB
Percentile within its GICS sector across the S&P 1500.
Growth1st percentile in sectorF
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Percentile within its GICS sector across the S&P 1500.
Profitability12th percentile in sectorD-
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.94 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
pricier
pricier
pricier
Forward EPS $-3.12 vs trailing $-3.91. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Piotroski F-score 0/9 · last two fiscal years
Altman Z-score -0.9 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $247.0M | $-353.0M | $-484.0M |
| 2024 | $258.0M | $-283.0M | $-176.0M |
| 2023 | $117.0M | $-307.0M | $-330.0M |
| 2022 | $112.0M | $-267.0M | $432.0M |
| 2021 | $383.0M | $53.0M | $-282.0M |
| 2020 | $78.0M | $-123.0M | $108.0M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +30.2%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | -0.81 | -0.72 | +11.6% |
| 2026-05-05 | -0.83 | -1.02 | -23.3% |
| 2026-02-25 | -1.07 | -0.89 | +17.2% |
| 2025-10-28 | -1.29 | -1.27 | +1.6% |
| 2025-05-06 | -1.01 | -1.14 | -12.6% |
| 2025-02-25 | -1.20 | -1.03 | +14.4% |
| 2024-11-06 | -1.07 | -1.00 | +6.3% |
| 2024-08-08 | -1.39 | -1.02 | +26.4% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $41.0M | -74.4% |
| 2026-03-31 | $17.0M | – |
| 2025-12-31 | $33.0M | – |
| 2025-09-30 | $26.0M | – |
| 2025-06-30 | $160.0M | – |
Analyst actions
PT $41
PT $43
PT $40
PT $26
Stats refreshed 2026-10-21 01:31:43 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026